Chimeric antigen receptor T-cell therapy-43 (Beijing Yongtai Ruike Biotechnology)

N/A

Report date: 2023/11/13 10:34:31

Base Information

Drug NameChimeric antigen receptor T-cell therapy-43 (Beijing Yongtai Ruike Biotechnology)
Drug Alias NameCAR-T-43
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionLeukosialin inhibitors
TargetsLeukosialin
Therapy Area/IndicationsLymphoma, T-CellLeukemia, T-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesImmunotech Applied Science Ltd
China Registration ClassN/A

Develop Information

Active CompaniesImmunotech Applied Science Ltd
Inactive CompaniesN/A
Active IndicationsLymphoma, T-CellLeukemia, T-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A